ɪn ɐdˈɪʃən, tˌiːˌɑːɹkˈeɪ bˈiː slˈæʃ bˌiːdˌiːˌɛnˈɛf sˈɪɡnəlɪŋ hˈæzbiːn ðə tˈɑːɹɡɪt fɔːɹ dɪvˈɛləpɪŋ nˈɑːvəl dɹˈʌɡz fɔːɹ ˈɑːltshaɪmɚz dɪzˈiːz, pˈɑːɹkɪnsənz dɪzˈiːz ɔːɹ ˈʌðɚ nˈʊɹɹoʊddʒˌɛnɚɹətˌɪv ænd sˌaɪkɪˈætɹɪk dɪsˈoːɹdɚz, ˈeɪmɪŋ æɾ ˈiːðɚ fˌɑːɹmɐkəlˈɑːdʒɪkəl mˌɑːdʒuːlˈeɪʃən ʌvðə pˈæθweɪ ˈiː.dʒˈiː. smˈɔːl mˈɑːlɪkjˌuːl maɪmˈɛɾɪks ɔːɹ ˈʌðɚ mˈiːnz ˈiː.dʒˈiː. ˈɛksɚsˌaɪz ɪndˈuːst tʃˈeɪndʒᵻz ɪn tˌiːˌɑːɹkˈeɪ bˈiː sˈɪɡnəlɪŋ.
In addition, TrkB/BDNF signalling has been the target for developing novel drugs for Alzheimer’s Disease, Parkinson’s Disease or other neurodegenerative and psychiatric disorders, aiming at either pharmacological modulation of the pathway (e.g. small molecule mimetics) or other means (e.g. exercise induced changes in TrkB signalling).